Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review

Collecting duct carcinoma (CDC) is a rare and highly aggressive subtype of kidney cancer that is associated with a poor prognosis. At present, there is no effective treatment for CDC. Herein, we report a case of metastatic CDC treated with a combination of a tyrosine kinase inhibitor and an immune c...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weimin Zhou, Ji Huang, Qiuming He, Qingfeng Luo, Xiaofang Zhang, Xuewei Tao, Hanzhi Dong, Xinhua Tu
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	collecting duct carcinoma kidney cancer immunotherapy targeted therapy immune checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/581596165b12475dbddb946f52abefa1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:581596165b12475dbddb946f52abefa1
record_format	dspace
spelling	oai:doaj.org-article:581596165b12475dbddb946f52abefa12021-11-08T07:03:58ZPersistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review2234-943X10.3389/fonc.2021.764352https://doaj.org/article/581596165b12475dbddb946f52abefa12021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.764352/fullhttps://doaj.org/toc/2234-943XCollecting duct carcinoma (CDC) is a rare and highly aggressive subtype of kidney cancer that is associated with a poor prognosis. At present, there is no effective treatment for CDC. Herein, we report a case of metastatic CDC treated with a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor. A 67-year-old male was diagnosed with CDC with lung and bone metastasis. Pazopanib and camrelizumab were administered after cytoreductive nephrectomy. The patient achieved a partial response after one cycle of treatment; however, he then experienced serious drug-induced hepatic injury. Therefore, we discontinued camrelizumab and administered monotherapy with pazopanib. Three months later, the cancer had progressed and axitinib and sintilimab were administered. The patient achieved a partial response, accompanied by the complete disappearance of the metastatic lesion in the lung. The patient had an excellent physical status after 11 months. This is the first reported case of metastatic CDC successfully treated with a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor. This form of combination treatment may be an effective option for treating metastatic CDC.Weimin ZhouJi HuangQiuming HeQingfeng LuoXiaofang ZhangXuewei TaoHanzhi DongXinhua TuFrontiers Media S.A.articlecollecting duct carcinomakidney cancerimmunotherapytargeted therapyimmune checkpoint inhibitorNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	collecting duct carcinoma kidney cancer immunotherapy targeted therapy immune checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	collecting duct carcinoma kidney cancer immunotherapy targeted therapy immune checkpoint inhibitor Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Weimin Zhou Ji Huang Qiuming He Qingfeng Luo Xiaofang Zhang Xuewei Tao Hanzhi Dong Xinhua Tu Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
description	Collecting duct carcinoma (CDC) is a rare and highly aggressive subtype of kidney cancer that is associated with a poor prognosis. At present, there is no effective treatment for CDC. Herein, we report a case of metastatic CDC treated with a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor. A 67-year-old male was diagnosed with CDC with lung and bone metastasis. Pazopanib and camrelizumab were administered after cytoreductive nephrectomy. The patient achieved a partial response after one cycle of treatment; however, he then experienced serious drug-induced hepatic injury. Therefore, we discontinued camrelizumab and administered monotherapy with pazopanib. Three months later, the cancer had progressed and axitinib and sintilimab were administered. The patient achieved a partial response, accompanied by the complete disappearance of the metastatic lesion in the lung. The patient had an excellent physical status after 11 months. This is the first reported case of metastatic CDC successfully treated with a combination of a tyrosine kinase inhibitor and an immune checkpoint inhibitor. This form of combination treatment may be an effective option for treating metastatic CDC.
format	article
author	Weimin Zhou Ji Huang Qiuming He Qingfeng Luo Xiaofang Zhang Xuewei Tao Hanzhi Dong Xinhua Tu
author_facet	Weimin Zhou Ji Huang Qiuming He Qingfeng Luo Xiaofang Zhang Xuewei Tao Hanzhi Dong Xinhua Tu
author_sort	Weimin Zhou
title	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
title_short	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
title_full	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
title_fullStr	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
title_full_unstemmed	Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review
title_sort	persistent response to a combination treatment featuring a targeted agent and an immune checkpoint inhibitor in a patient with collecting duct renal carcinoma: a case report and literature review
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/581596165b12475dbddb946f52abefa1
work_keys_str_mv	AT weiminzhou persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT jihuang persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT qiuminghe persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT qingfengluo persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT xiaofangzhang persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT xueweitao persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT hanzhidong persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview AT xinhuatu persistentresponsetoacombinationtreatmentfeaturingatargetedagentandanimmunecheckpointinhibitorinapatientwithcollectingductrenalcarcinomaacasereportandliteraturereview
_version_	1718442910130634752

Persistent Response to a Combination Treatment Featuring a Targeted Agent and an Immune Checkpoint Inhibitor in a Patient With Collecting Duct Renal Carcinoma: A Case Report and Literature Review

Ejemplares similares